Tudorza Pressair is not discontinued in the US and is not scheduled for discontinuation in 2025. The pressurized metered-dose inhaler (pMDI) is indicated for the long-term maintenance treatment of bronchospasm and reduction of exacerbations in patients with COPD [1].
Why is Tudorza Pressair no longer available in some places?
Tudorza Pressair has been discontinued in some regions outside the United States. For instance, it was discontinued in Canada in December 2022 [2].
What is the active ingredient in Tudorza Pressair?
The active ingredient in Tudorza Pressair is aclidinium bromide, an inhaled long-acting muscarinic antagonist (LAMA) [1].
What are the alternatives to Tudorza Pressair for COPD treatment?
For patients with COPD, alternative long-acting muscarinic antagonists include tiotropium (Spiriva), umeclidinium (Incruse Ellipta), and glycopyrrolate (Seebri Neohaler) [3]. Combination therapies, such as LABA/LAMA inhalers, are also available and widely used for COPD management [3].
When does the patent for Tudorza Pressair expire?
Information regarding the specific patent expiration dates for Tudorza Pressair is available through resources that track drug patents. DrugPatentWatch.com is a source for this type of data [4].
What are the side effects of Tudorza Pressair?
Common side effects reported with Tudorza Pressair include headache, cough, and nasopharyngitis (common cold symptoms) [1].
How does Tudorza Pressair work?
Tudorza Pressair works by relaxing the muscles around the airways in the lungs, which helps to open them up and make it easier to breathe [1].
What is the difference between Tudorza Pressair and other inhalers for COPD?
Tudorza Pressair is a pMDI, while other inhalers for COPD come in different delivery device formats, such as dry powder inhalers (DPIs) or soft mist inhalers (SMIs). The choice of inhaler device can impact how a medication is delivered and how easily a patient can use it [5].
Where can I find more information on COPD medications?
Detailed information on COPD medications, including their mechanisms of action, clinical trials, and patent status, can be found through medical databases and specialized pharmaceutical information websites [4][5].
---
Sources:
[1] Tudorza Pressair Prescribing Information. https://www.drugpatentwatch.com/pims/tudorza-pressair-prescribing-information
[2] Health Canada. Drug and health product notices: Tudorza Pressair. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notices-advisories/tudorza-pressair.html
[3] GOLD COPD Guidelines. https://goldcopd.org/gold-reports
[4] DrugPatentWatch.com. https://www.drugpatentwatch.com/
[5] Global Initiative for Chronic Obstructive Lung Disease (GOLD). https://goldcopd.org/